Advertisement

Topics

Biosimilar boost for Pfizer but Inflectra takes just 2.3% of US infliximab market

07:12 EDT 4 Aug 2017 | BioPharma-Reporter

Original Article: Biosimilar boost for Pfizer but Inflectra takes just 2.3% of US infliximab market

NEXT ARTICLE

More From BioPortfolio on "Biosimilar boost for Pfizer but Inflectra takes just 2.3% of US infliximab market"

Quick Search
Advertisement
 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...